Size of Sonic Healthcare's German Lab Acquisition Raises Antitrust Concerns, May Force Some Divestitures, Jarden Research Says

MT Newswires Live

2024/12/12

The size of Sonic Healthcare's (ASX:SHL) acquisition of the LADR Laboratory Group Dr. Kramer & Colleagues in Germany raises antitrust issues that may force some divestitures, potentially impacting the economics of the acquisition, Jarden Research said in a Tuesday note.

Sonic Healthcare recently disclosed that it will acquire the laboratory testing services provider for 423 million euros and expects the acquisition to be immediately accretive to earnings per share.

The investment firm notes that the acquisition will increase the company's German revenue by about 34% in 2024, which is expected to increase in 2027 once the entire acquisition is complete.

The firm also believes that due to the size of this acquisition, the company is likely to "cap out" its ability to continue to acquire in Germany.

Jarden Research maintained its neutral rating on the company and raised its target price to AU$29.04 from AU$28.06.

Price (AUD): $28.34, Change: $+0.06, Percent Change: +0.21%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2490429810"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490429810\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490429810?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 08:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490429810","market":"sh","top_or_hot":-1,"title":"Size of Sonic Healthcare's German Lab Acquisition Raises Antitrust Concerns, May Force Some Divestitures, Jarden Research Says","media":"MT Newswires Live","content":"<html><body><p> The size of Sonic Healthcare's (ASX:SHL) acquisition of the LADR Laboratory Group Dr. Kramer &amp; Colleagues in Germany raises antitrust issues that may force some divestitures, potentially impacting the economics of the acquisition, Jarden Research said in a Tuesday note.</p><p>Sonic Healthcare recently disclosed that it will acquire the laboratory testing services provider for 423 million euros and expects the acquisition to be immediately accretive to earnings per share.</p><p>The investment firm notes that the acquisition will increase the company's German revenue by about 34% in 2024, which is expected to increase in 2027 once the entire acquisition is complete.</p><p>The firm also believes that due to the size of this acquisition, the company is likely to \"cap out\" its ability to continue to acquire in Germany.</p><p>Jarden Research maintained its neutral rating on the company and raised its target price to AU$29.04 from AU$28.06.</p><p>Price (AUD): $28.34, Change: $+0.06, Percent Change: +0.21%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Size of Sonic Healthcare's German Lab Acquisition Raises Antitrust Concerns, May Force Some Divestitures, Jarden Research Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSize of Sonic Healthcare's German Lab Acquisition Raises Antitrust Concerns, May Force Some Divestitures, Jarden Research Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-12 08:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The size of Sonic Healthcare's (ASX:SHL) acquisition of the LADR Laboratory Group Dr. Kramer &amp; Colleagues in Germany raises antitrust issues that may force some divestitures, potentially impacting the economics of the acquisition, Jarden Research said in a Tuesday note.</p><p>Sonic Healthcare recently disclosed that it will acquire the laboratory testing services provider for 423 million euros and expects the acquisition to be immediately accretive to earnings per share.</p><p>The investment firm notes that the acquisition will increase the company's German revenue by about 34% in 2024, which is expected to increase in 2027 once the entire acquisition is complete.</p><p>The firm also believes that due to the size of this acquisition, the company is likely to \"cap out\" its ability to continue to acquire in Germany.</p><p>Jarden Research maintained its neutral rating on the company and raised its target price to AU$29.04 from AU$28.06.</p><p>Price (AUD): $28.34, Change: $+0.06, Percent Change: +0.21%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SHL.AU","symbol_name":"SONIC HEALTHCARE LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490429810","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490429810","pubTimestamp":1733963064,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The size of Sonic Healthcare's  acquisition of the LADR Laboratory Group Dr. Kramer & Colleagues in Germany raises antitrust issues that may force some divestitures, potentially impacting the economics of the acquisition, Jarden Research said in a Tuesday note.Sonic Healthcare recently disclosed that it will acquire the laboratory testing services provider for 423 million euros and expects the acquisition to be immediately accretive to earnings per share.The investment firm notes that the acquisition will increase the company's German revenue by about 34% in 2024, which is expected to increase in 2027 once the entire acquisition is complete.The firm also believes that due to the size of this acquisition, the company is likely to \"cap out\" its ability to continue to acquire in Germany.Jarden Research maintained its neutral rating on the company and raised its target price to AU$29.04 from AU$28.06.Price : $28.34, Change: $+0.06, Percent Change: +0.21%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SHL.AU":"SONIC HEALTHCARE LTD","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","BK7124":"保健护理服务","HCSG":"Healthcare Svcs Group Inc","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","BK4125":"广播","BK4137":"综合支持服务"},"translate_title":"Jarden Research表示，Sonic Healthcare收购德国实验室的规模引发了反垄断担忧，可能会迫使一些资产剥离","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SHL.AU":1,"HCSG":1,"AUD":1},"content_text":"The size of Sonic Healthcare's (ASX:SHL) acquisition of the LADR Laboratory Group Dr. Kramer & Colleagues in Germany raises antitrust issues that may force some divestitures, potentially impacting the economics of the acquisition, Jarden Research said in a Tuesday note.Sonic Healthcare recently disclosed that it will acquire the laboratory testing services provider for 423 million euros and expects the acquisition to be immediately accretive to earnings per share.The investment firm notes that the acquisition will increase the company's German revenue by about 34% in 2024, which is expected to increase in 2027 once the entire acquisition is complete.The firm also believes that due to the size of this acquisition, the company is likely to \"cap out\" its ability to continue to acquire in Germany.Jarden Research maintained its neutral rating on the company and raised its target price to AU$29.04 from AU$28.06.Price (AUD): $28.34, Change: $+0.06, Percent Change: +0.21%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}